Reclast (Zoledronic Acid) in Adults 65 and Older: Off-Label Uses, Evidence, and Dosing

What Is Zoledronic Acid and Why Is It Used Off-Label in Older Adults?

Zoledronic acid is the most potent nitrogen-containing bisphosphonate in clinical use. A single 5 mg intravenous infusion suppresses osteoclast-mediated bone resorption for 12 months or longer, which makes annual dosing practical for patients who cannot tolerate or reliably take oral bisphosphonates. The FDA has approved it for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget disease of bone, as well as for hypercalcemia of malignancy and bone metastases under the Zometa brand at a 4 mg dose.

Off-label prescribing in adults over 65 arises because the boundaries of the FDA label do not always map cleanly onto clinical reality. Many older patients develop bone loss from aromatase inhibitors, androgen deprivation therapy, or long-term glucocorticoids at doses just below the label threshold, or they present after a hip fracture when randomized trial data strongly support bisphosphonate therapy even though the specific post-fracture indication is not formally labeled.

The FDA drug label for zoledronic acid acknowledges that clinical studies enrolled patients up to age 90, giving prescribers reasonable pharmacokinetic and safety data across the older-adult spectrum. Still, prescribing beyond the labeled indications requires explicit risk-benefit documentation.

How Zoledronic Acid Works

Zoledronic acid binds avidly to hydroxyapatite at bone-resorption sites. Once internalized by osteoclasts, it inhibits farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and triggering osteoclast apoptosis. This mechanism is shared by other bisphosphonates, but zoledronic acid's binding affinity is roughly 100-fold higher than alendronate, which explains the durability of a once-yearly dose [1].

FDA-Approved vs. Off-Label Boundaries

The on-label indications for the 5 mg Reclast formulation include:

• Postmenopausal osteoporosis (treatment and prevention)
• Osteoporosis in men to increase bone mass
• Glucocorticoid-induced osteoporosis in patients taking prednisone 7.5 mg/day or equivalent for at least 12 months
• Paget disease of bone in adults

Off-label geriatric applications discussed in this article include secondary fracture prevention after hip fracture, aromatase inhibitor-associated bone loss (AIBL), cancer treatment-induced bone loss (CTIBL) in non-metastatic settings, and osteoporosis in men receiving androgen deprivation therapy (ADT) who do not meet the formal label criteria.

HORIZON-PFT: The Foundational Trial for Older Adults

The HORIZON Key Fracture Trial (HORIZON-PFT) remains the most cited evidence base for zoledronic acid in the geriatric population. Published in the New England Journal of Medicine in 2007, HORIZON-PFT enrolled 7,736 postmenopausal women with osteoporosis (mean age 73 years, range 65-89) and randomized them to zoledronic acid 5 mg IV annually or placebo for 3 years [2].

The primary results showed a 70% relative risk reduction in morphometric vertebral fractures (3.3% vs. 10.9%, P<0.001), a 41% relative risk reduction in hip fractures (1.4% vs. 2.5%, P<0.001), and a 25% reduction in any clinical fracture [2]. These effect sizes were consistent across patients aged 65-74 and 75 and older, which is directly relevant to geriatric off-label decision-making.

The HORIZON-RFT Hip Fracture Secondary Prevention Sub-Study

A separate HORIZON sub-trial, the Recurrent Fracture Trial (HORIZON-RFT), addressed what is arguably the most common geriatric off-label scenario: a patient who has just suffered a hip fracture. HORIZON-RFT enrolled 2,127 patients (mean age 74.5 years) who had undergone surgical repair of a low-trauma hip fracture within 90 days. Zoledronic acid 5 mg or placebo was given starting at least 2 weeks post-surgery.

At a median follow-up of 1.9 years, zoledronic acid reduced the rate of any new clinical fracture by 35% (8.6% vs. 13.9%, P<0.001) and reduced all-cause mortality by 28% (9.6% vs. 13.3%, P=0.01) [3]. The mortality benefit was unexpected and has been attributed partly to reductions in subsequent fractures and partly to possible pleiotropic anti-inflammatory effects.

This trial provides the strongest evidence base for the off-label use of zoledronic acid in older adults immediately after hip fracture, since post-hip-fracture initiation is not explicitly included in the FDA label for Reclast.

What the HORIZON Long-Term Extension Showed

A 6-year extension of HORIZON-PFT found that patients who received zoledronic acid for 6 years had a lower rate of vertebral fractures than those who discontinued after 3 years (2.0% vs. 3.0%, P=0.06), though non-vertebral fracture rates were similar [4]. The American Society for Bone and Mineral Research (ASBMR) task force recommends reassessing at 3 years in lower-risk patients and continuing to 6 years in those with high fracture risk. For older patients who began therapy after age 70 with T-scores below -2.5 at the femoral neck, continuation beyond 3 years is generally supported by this extension data.

Aromatase Inhibitor-Associated Bone Loss in Older Women

Aromatase inhibitors (AIs), including anastrozole, letrozole, and exemestane, are standard adjuvant therapy for hormone receptor-positive breast cancer in postmenopausal women. AI therapy suppresses residual estrogen production and accelerates bone loss at roughly twice the rate seen in normal postmenopausal aging, producing lumbar spine bone mineral density (BMD) decreases of 2-3% per year [5].

For older patients already starting from a lower BMD baseline, this additional loss can push them across fracture-risk thresholds quickly. The AIBL off-label application of zoledronic acid is therefore one of the most clinically common scenarios in oncology-adjacent geriatric care.

Evidence from the Z-FAST and ZO-FAST Trials

The ZO-FAST trial randomized 1,065 postmenopausal women on letrozole to upfront zoledronic acid 4 mg every 6 months (off-label dose for this non-metastatic indication) vs. Delayed treatment triggered by BMD decline or fracture. At 5 years, the upfront group had a 4.4% higher lumbar spine BMD and 3.5% higher total hip BMD compared with the delayed group [5]. The trial was conducted using Zometa dosing, but clinical practice has migrated toward annual Reclast 5 mg dosing based on pharmacodynamic equivalence arguments. No fracture-endpoint trial with Reclast specifically in the AIBL setting has been completed, which is why this remains an off-label use.

Practical Thresholds for Treatment

The 2022 American Society of Clinical Oncology guideline on bone health in breast cancer recommends initiating bisphosphonate therapy when T-score is below -2.0, when two or more clinical risk factors for fracture are present, or after any fragility fracture while on AI therapy [6]. In practice, many oncologists and endocrinologists use zoledronic acid 5 mg IV annually for this indication in patients over 65, even when T-score is between -1.0 and -2.0, if FRAX 10-year hip fracture probability exceeds 3%.

Cancer Treatment-Induced Bone Loss in Men on ADT

Androgen deprivation therapy for prostate cancer accelerates bone loss and fracture risk substantially. Men on ADT lose BMD at 2-4% per year at the spine and 1-2% per year at the hip, and cumulative fracture incidence over 5 years of ADT can reach 19% [7].

The FDA label for Reclast includes osteoporosis in men to increase bone mass, but does not specifically mention ADT-associated bone loss. Prescribing zoledronic acid for men on ADT is therefore partially on-label (if osteoporosis is confirmed by DXA) and partially off-label (if initiated for prevention at osteopenia thresholds in the ADT context).

ZEUS Trial Data

The Zoledronic acid EUsing in Subjects trial (ZEUS) enrolled 176 men on ADT for non-metastatic prostate cancer and found that zoledronic acid 4 mg IV every 3 months for 1 year (Zometa dosing, off-label frequency) increased lumbar spine BMD by 5.6% vs. A 2.2% decrease in placebo (P<0.001) [8]. Annual Reclast 5 mg dosing produces comparable BMD gains with a simpler schedule and is preferred in outpatient geriatric settings.

When to Start in Older Men

Clinicians should obtain baseline DXA and calculate FRAX in men starting ADT, particularly those over 65. The American Urological Association and the Endocrine Society both acknowledge that bisphosphonate initiation at osteopenia thresholds (T-score -1.0 to -2.5) may be appropriate in men on ADT given the additional fracture-risk burden, though formal label criteria require T-score below -2.5 or a prevalent fragility fracture [9].

Geriatric Safety Considerations Specific to Patients Over 65

Older adults face a distinct set of safety considerations compared with younger bisphosphonate users. Renal function declines with age, polypharmacy is common, and immobility or dehydration episodes occur more frequently.

Renal Safety and Monitoring

The FDA label contraindications zoledronic acid when creatinine clearance is below 35 mL/min. In adults over 75, CrCl can fall below this threshold even when serum creatinine appears normal due to reduced muscle mass. Calculating CrCl using the Cockcroft-Gault equation with actual body weight is mandatory before each infusion.

A 2015 analysis of HORIZON-PFT data found that patients with CrCl 35-60 mL/min at baseline had no statistically significant increase in adverse renal events compared with patients with CrCl above 60 mL/min, provided they received adequate pre-infusion hydration [10]. Still, repeat CrCl measurement within 10 days after infusion is advisable in patients with baseline CrCl below 50 mL/min.

Acute-Phase Reactions

Approximately 32% of patients experience an acute-phase reaction (fever, myalgia, headache, arthralgia) after the first infusion. The incidence drops to roughly 7% after the second infusion and continues to decline with subsequent doses [2]. Acetaminophen 650 mg every 6 hours for 72 hours after infusion reduces symptom severity. In frail older adults, a higher fever threshold for clinical concern should be communicated to caregivers before the patient leaves the infusion suite.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) occurs at an estimated rate of 0.02% per year with osteoporosis-dose bisphosphonate therapy, far lower than the 0.7-6.7% rate seen with high-frequency oncologic dosing [11]. Older adults are at modestly higher risk due to higher rates of dental disease and denture use. The AAOMS position paper on medication-related ONJ recommends completing any invasive dental procedures at least 4 weeks before starting zoledronic acid when possible, and delaying elective dental surgery in patients currently receiving therapy pending clinical judgment [11].

Atypical Femur Fractures

Atypical subtrochanteric or diaphyseal femur fractures are a rare adverse event associated with prolonged bisphosphonate use. The absolute risk is estimated at 3.2-50 per 100,000 person-years, increasing with duration of use beyond 5 years [12]. Older patients reporting new thigh or groin pain during bisphosphonate therapy should undergo bilateral femur radiographs. A bisphosphonate drug holiday of 1-3 years is generally recommended after 5 years of treatment in patients at moderate fracture risk, per the ASBMR task force guidance.

Practical Dosing and Administration for Off-Label Geriatric Use

Off-label dosing in older adults generally follows the approved Reclast schedule because it has the most supporting data in this age group. The 4 mg Zometa schedule used in oncology trials is not interchangeable with the 5 mg Reclast infusion for metabolic bone disease indications.

Pre-Infusion Checklist

1. Confirm CrCl at least 35 mL/min within 30 days of infusion
2. Check serum 25-OH-D and correct deficiency (target above 20 ng/mL) before dosing
3. Verify calcium intake is at least 1,000 mg per day from diet plus supplements
4. Instruct patient to drink at least 500 mL of water or normal saline within 2 hours before infusion
5. Complete any pending invasive dental procedures at least 4 weeks before first infusion when feasible

Infusion Details

Reclast 5 mg is administered as a 100 mL ready-to-infuse solution over at least 15 minutes. Faster infusion rates have been associated with increased renal adverse events. Patients should remain in the infusion suite for at least 30 minutes post-infusion for monitoring, longer in frail patients with borderline renal function.

Monitoring After Infusion

A post-infusion visit or telehealth check at 2-4 weeks is reasonable practice in older adults to assess for delayed acute-phase reactions, new musculoskeletal complaints, and any signs of hypocalcemia. Repeat DXA at 1-2 years confirms BMD response. A lack of BMD increase after two annual infusions should prompt reassessment of treatment adherence, calcium and vitamin D status, and secondary causes of bone loss.

Special Population: Frail Older Adults and Those in Long-Term Care

Frail older adults present a unique clinical picture. They often have the highest fracture risk but also the most comorbidities. Data from a post-hoc analysis of HORIZON-RFT showed that even patients with a Clinical Frailty Scale score of 4-5 derived significant fracture-reduction benefit from zoledronic acid, with no statistically significant increase in serious adverse events compared with placebo [3].

For patients in long-term care or those who cannot attend outpatient infusion centers, mobile infusion services can administer Reclast at the facility. The same pre-infusion hydration and renal monitoring requirements apply.

The National Osteoporosis Foundation clinical guide emphasizes that age alone should not be a reason to withhold bisphosphonate therapy, provided renal function is adequate and the patient or their decision-maker understands the risk-benefit profile [13]. Patients aged 85 and older with T-scores below -2.5 and prior fractures have among the highest absolute fracture risks, which means the number needed to treat to prevent one fracture is often lower in this group than in younger postmenopausal women.

Comparing Zoledronic Acid to Other Agents in Older Adults

For patients over 65 who cannot receive intravenous therapy or who have CrCl between 30-35 mL/min, alternatives include denosumab, which requires no renal dose adjustment and is given as a 60 mg subcutaneous injection every 6 months. However, denosumab carries a rebound vertebral fracture risk if discontinued without transitioning to a bisphosphonate, which makes it a more complex long-term choice in patients with cognitive impairment or unreliable follow-up.

Romosozumab (Evenity) is approved for high-risk postmenopausal osteoporosis but carries a boxed warning for cardiovascular events, limiting its use in older patients with established coronary artery disease or stroke history. A 2023 meta-analysis in JAMA Network Open found that romosozumab followed by alendronate reduced vertebral fracture risk by 75% compared with alendronate alone over 24 months, but the cardiovascular warning remains a practical barrier in multimorbid older adults [14].

For most geriatric patients, zoledronic acid 5 mg annually remains the preferred intravenous bisphosphonate because its efficacy data derive primarily from trials enrolling patients in the 65-89 age range, and the once-yearly schedule eliminates adherence problems that plague daily oral regimens.

Physician and Guideline Perspectives on Off-Label Use

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines for postmenopausal osteoporosis state: "Zoledronic acid 5 mg IV annually is a first-line pharmacologic option for patients unable to use oral bisphosphonates and for those at very high fracture risk requiring reliable drug delivery." This statement applies directly to many adults over 65 in whom daily oral dosing is impractical [15].

The 2023 Endocrine Society clinical practice guideline on osteoporosis in men states that bisphosphonate therapy should be offered to men with osteoporosis and to men with osteopenia who are at high fracture risk based on FRAX scores, explicitly including men on ADT as a high-risk subgroup warranting pharmacologic intervention [9].

Regarding the post-hip-fracture off-label scenario, the American Orthopaedic Association's "Own the Bone" program and the American Geriatrics Society both recommend initiating or continuing bisphosphonate therapy as part of standardized post-fracture care pathways, acknowledging that the mortality benefit seen in HORIZON-RFT strengthens the case for zoledronic acid specifically [3].